drugset / Trial / NCT01647971
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab.
Timeline
- Start
- 2012-07-19
- Primary completion
- 2015-05
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ublituximab | Monoclonal antibody | 600 mg | Intravenous |
| Subject | Ublituximab | Monoclonal antibody | 900 mg | Intravenous |
| Subject | Ublituximab | Monoclonal antibody | 1200 mg | Intravenous |